HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Antonini, A. Articles by Leenders, K. L. Search for Related Content PubMed PubMed Citation Articles by Antonini, A. Articles by Leenders, K. L.

[¹¹C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease

Influence of L-dopa and lisuride therapy on striatal dopamine D₂-receptors

PET Department (Drs. Antonini and Leenders) and the Radiopharmacy Division (Dr. Beer), Paul Scherrer Institute, Villigen, Switzerland; the Department of Neurology (Drs. Schwarz and Oertel), Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany; and Schering Pharma Deutschland (Dr. Madeja), Berlin, Germany.

We studied cerebral dopamine D₂-receptor binding using [¹¹C]raclopride and PET in 18 previously untreated patients with Parkinson's disease (PD) and 14 healthy volunteer subjects. Sixteen patients were scanned before and after 3 to 4 months of stable oral therapy with either L-dopa (300 mg/d) (n = 7) or lisuride (0.8 to 1.2 mg/d) (n = 9). Two additional patients were investigated before and after a continuous IV infusion of L-dopa. In addition, we studied the effect of acute IV L-dopa and lisuride administration on [¹¹C]raclopride binding in a healthy rhesus monkey. At baseline, PD patients showed higher uptake values in the putamen than did healthy subjects (p < 0.0001). Oral lisuride treatment lowered [¹¹C]raclopride uptake in the putamen (-19%) and in the caudate nucleus (-15%) compared with baseline, but the difference did not reach significance upon Bonferroni correction for multiple comparisons. However, putamen tracer uptake returned to baseline in two patients when we repeated [¹¹C]raclopride scans 4 days after lisuride withdrawal. Oral L-dopa treatment did not induce changes in the putamen or caudate nucleus indices. Acute lisuride (25 µg) administration in a healthy monkey reduced striatal uptake values, but acute injection of L-dopa (300 mg) did not. The results suggest that lisuride blocks [ⁿC]raclopride binding at dopamine D₂-receptor sites and demonstrate that 3 to 4 months' oral therapy with L-dopa or lisuride does not change striatal dopamine D₂-receptor density in PD patients.

Address correspondence and reprint requests to Dr. K.L. Leenders, PET Department, Paul Scherrer Institute, CH-5232 Villigen, Switzerland.

Supported in part by Schering AG Berlin. J.S. was supported by BMFT program Munich 01 IC 9001, "Morbus Parkinson and other basal ganglia disorders."

Received July 27, 1993. Accepted in final form January 18, 1994.

This article has been cited by other articles:

				G. Linazasoro Pathophysiology of Motor Complications in Parkinson Disease: Postsynaptic Mechanisms Are Crucial Arch Neurol, January 1, 2007; 64(1): 137 - 140. [Full Text] [PDF]

				M. Slifstein, D.-R. Hwang, D. Martinez, J. Ekelund, Y. Huang, E. Hackett, A. Abi-Dargham, and M. Laruelle Biodistribution and Radiation Dosimetry of the Dopamine D2 Ligand 11C-Raclopride Determined from Human Whole-Body PET J. Nucl. Med., February 1, 2006; 47(2): 313 - 319. [Abstract] [Full Text] [PDF]

				S. Thobois, F. Vingerhoets, V. Fraix, J. Xie-Brustolin, H. Mollion, N. Costes, P. Mertens, A.-L. Benabid, P. Pollak, and E. Broussolle Role of Dopaminergic Treatment in Dopamine Receptor Down-regulation in Advanced Parkinson Disease: A Positron Emission Tomographic Study Arch Neurol, November 1, 2004; 61(11): 1705 - 1709. [Abstract] [Full Text] [PDF]

				M Ghaemi, R Hilker, J Rudolf, J Sobesky, and W-D Heiss Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging J. Neurol. Neurosurg. Psychiatry, November 1, 2002; 73(5): 517 - 523. [Abstract] [Full Text] [PDF]

				A.T. Portman, N. Giladi, K.L. Leenders, P. Maguire, L. Veenma-van der Duin, J. Swart, J. Pruim, E.S. Simon, S. Hassin-Baer, and A.D. Korczyn The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations Neurology, June 26, 2001; 56(12): 1759 - 1762. [Abstract] [Full Text] [PDF]

				V. Kaasinen, K. Nagren, J. Hietala, V. Oikonen, H. Vilkman, L. Farde, C. Halldin, and J. O. Rinne Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease Neurology, April 11, 2000; 54(7): 1482 - 1487. [Abstract] [Full Text] [PDF]

				A. Samii, K. Markopoulou, Z. K. Wszolek, V. Sossi, T. Dobko, E. Mak, D. B. Calne, and A. J. Stoessl PET studies of parkinsonism associated with mutation in the {alpha}-synuclein gene Neurology, December 1, 1999; 53(9): 2097 - 2097. [Abstract] [Full Text]

				K. Marek Dopaminergic Dysfunction in Parkinsonism: New Lessons from Imaging Neuroscientist, September 1, 1999; 5(5): 333 - 340. [Abstract] [PDF]

				M. A. Piggott, E. F. Marshall, N. Thomas, S. Lloyd, J. A. Court, E. Jaros, D. Burn, M. Johnson, R. H. Perry, I. G. McKeith, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution Brain, August 1, 1999; 122(8): 1449 - 1468. [Abstract] [Full Text] [PDF]

				M. Ichise, Y. J. Kim, J. R. Ballinger, D. Vines, S. S. Erami, F. Tanaka, and A. E. Lang SPECT imaging of pre- and postsynaptic dopaminergic alterations in L-dopa-untreated PD Neurology, April 1, 1999; 52(6): 1206 - 1206. [Abstract] [Full Text] [PDF]